Douglass Winthrop Advisors LLC boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,886 shares of the biopharmaceutical company’s stock after buying an additional 111 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Pfizer were worth $1,676,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer during the second quarter valued at $102,000. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer during the first quarter valued at $121,000. Cascade Investment Advisors Inc. boosted its stake in shares of Pfizer by 89.1% during the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 2,200 shares during the period. Finally, Perennial Advisors LLC boosted its stake in shares of Pfizer by 7.9% during the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 376 shares during the period. 69.34% of the stock is owned by institutional investors.

PFE has been the subject of a number of recent analyst reports. BMO Capital Markets reissued a “buy” rating and set a $37.00 target price on shares of Pfizer in a research note on Wednesday, September 6th. UBS AG reissued a “buy” rating and set a $38.00 target price on shares of Pfizer in a research note on Monday, July 31st. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, September 19th. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a research note on Tuesday, October 3rd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and an average target price of $38.48.

In other news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the transaction, the insider now owns 132,124 shares in the company, valued at approximately $4,492,216. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 366,557 shares of company stock worth $12,532,406. Corporate insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Pfizer, Inc. (PFE) Holdings Lifted by Douglass Winthrop Advisors LLC” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/23/pfizer-inc-pfe-holdings-lifted-by-douglass-winthrop-advisors-llc.html.

Pfizer, Inc. (PFE) opened at $35.43 on Thursday. The company has a market cap of $211,843.53, a PE ratio of 14.22, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer, Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the previous year, the company posted $0.61 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. equities analysts predict that Pfizer, Inc. will post 2.6 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.61%. Pfizer’s dividend payout ratio (DPR) is currently 79.01%.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.